NYSE · VRTX
Healthcare · Biotechnology
$514.63
Down-$4.88 (-0.94%)
Updated Sep 16, 2026, 11:57 AM
SID Score
6.7/10
Composite research score
Smart Money
59/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
VRTX closed at $514.63 after 20 trading sessions, down 2.57% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $519.94 | $519.94 | $511.001 | $514.63 | 824.89K |
| Sep 14, 2026 | $522.17 | $525.29 | $514.655 | $519.51 | 837.11K |
| Sep 11, 2026 | $522.10 | $522.10 | $511.81 | $515.44 | 875.64K |
| Sep 10, 2026 | $519.13 | $522.60 | $514.32 | $514.56 | 815.17K |
| Sep 9, 2026 | $524.00 | $528.165 | $520.08 | $521.12 | 958.51K |
| Sep 8, 2026 | $529.64 | $535.00 | $520.20 | $528.90 | 1.12M |
| Sep 4, 2026 | $549.50 | $556.99 | $544.48 | $546.12 | 803.52K |
| Sep 3, 2026 | $559.00 | $560.25 | $551.61 | $557.96 | 800.96K |
| Sep 2, 2026 | $552.42 | $558.36 | $549.07 | $556.75 | 1.73M |
| Sep 1, 2026 | $548.60 | $551.40 | $545.08 | $547.65 | 735.12K |
| Aug 31, 2026 | $535.38 | $546.84 | $532.2281 | $544.52 | 1.2M |
| Aug 28, 2026 | $547.09 | $549.57 | $540.08 | $541.69 | 886.92K |
| Aug 27, 2026 | $540.08 | $550.83 | $540.08 | $547.55 | 844.62K |
| Aug 26, 2026 | $549.84 | $553.47 | $546.235 | $547.29 | 834.38K |
| Aug 25, 2026 | $545.53 | $555.69 | $543.75 | $552.85 | 775.04K |
| Aug 24, 2026 | $548.98 | $550.615 | $542.42 | $547.59 | 767.49K |
| Aug 21, 2026 | $545.10 | $555.32 | $540.70 | $548.05 | 1.07M |
| Aug 20, 2026 | $543.78 | $548.985 | $538.27 | $540.26 | 1.06M |
| Aug 19, 2026 | $537.47 | $553.69 | $532.55 | $552.06 | 1.44M |
| Aug 18, 2026 | $520.00 | $533.78 | $517.3401 | $528.19 | 1.5M |
The latest Smart Investors Daily articles mentioning VRTX.
VRTX research
Company profile and research snapshot.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 11, 2026 | JP Morgan | Overweight | — |
| Sep 2, 2026 | Morgan Stanley | Overweight | — |
| Aug 5, 2026 | Truist Securities | Buy | — |
| Aug 5, 2026 | Barclays | Overweight | — |
| Aug 4, 2026 | TD Cowen | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 12, 2026
Vertex Pharmaceuticals (NASDAQ:VRTX) highlighted a series of upcoming clinical, regulatory and commercial catalysts across renal disease, pain management, cystic fibrosis and endocrinology during a Wells Fargo healthcare conference appearance. Susie Lisa, the company’s head of investor relations, s
Yahoo · Sep 12, 2026
Vertex Pharmaceuticals (NASDAQ:VRTX) outlined a broadening commercial and clinical strategy at the Cantor Global Healthcare Conference, highlighting its recent Crinetics acquisition, planned renal product launch efforts and upcoming pipeline milestones across kidney disease, pain, cystic fibrosis an
Yahoo · Sep 11, 2026
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition of Crinetics Pharmaceuticals. The deal gives the company immediate exposure to the endocrinology market and provides a new commercial platform beyond its established cystic fibrosis franchise. Vertex Expands Into Endocrinology On September 3, Citigroup […]
Yahoo · Sep 11, 2026
Since 2008, Vertex Pharmaceuticals, Inc. (VRTX) shares have received 42 outlier institutional inflow signals and gained over 1,682%.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VRTX.
